drugset
drugset / Trial / NCT00585312

Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

NCT00585312 ↗

Phase 3 Terminated 106 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindPrevention

Summary

To test whether celecoxib can be used to prevent colon polyp formation in children with familial adenomatous polyposis (FAP).

Timeline

Start
2006-09
Primary completion
2013-10
Completion
2013-10

Outcome

Outcome not reported

Stopped: “See termination reason in detailed description.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 16 mg/kg —

Indications

classic or attenuated familial adenomatous polyposis